Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
Science is only just getting to grips with the fact that 90% of our body is made up of bacteria – the microbiome. Bengt Saelensminde investigates.
Stephen O’Hara’s biotech company Optibiotix aims to profit from the ‘human microbiome’. David Thornton explains what that is, and what it means for investors.
We live in a golden age of unprecedented technological change. Smart investors should get in early, says Jim Mellon.
Technological change is everywhere, says Merryn Somerset Webb. Investors who don’t want to be left behind should read Jim Mellon’s new book.
Biotech companies will soon be able to get new drugs to patients much faster. That’s good news for patients and investors, says Matthew Partridge.
The best way to improve cancer treatment is early diagnosis. And this small-cap biotech company may have the key to doing just that, says Matthew Partridge.
A new kind of cancer therapy could make a big difference to survival rates – and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
As life expectancy increases, pharmas and biotechs pioneering treatments for the diseases of old age will profit handsomely, says Matthew Partridge.
The list of holdings in Neil Woodford’s new fund can teach investors a lot about how to construct a portfolio, says David Thornton.
The number of antibiotic-resistant bacteria is rising fast. But the search is on to find new drugs to combat them. Matthew Partridge explains how you could profit.